Sandeep Kunwar
Endocrinology, Diabetes & Metabolism · Hermiston, ORNPI 1760907505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 117 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations.
Across 117 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$435
- Boehringer Ingelheim$296
- AstraZeneca$230
- Novo Nordisk$214
- Novartis$176
- Medtronic$130
- plus $917 from 22 others
What the payments were for
- Food & beverage$2,396100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 19 | $435 |
| Boehringer Ingelheim | 12 | $296 |
| AstraZeneca(2 entities) | 13 | $230 |
| Novo Nordisk | 13 | $214 |
| Novartis | 9 | $176 |
| Medtronic | 7 | $130 |
| Sanofi-aventis U.S. LLC | 5 | $120 |
| Amgen(2 entities) | 6 | $111 |
| GSK | 4 | $93 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $67 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $46 |
| Dexcom, Inc. | 2 | $45 |
| Lilly USA, LLC | 2 | $36 |
| AbbVie | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Cequr Corporation | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$116
How this compares
$2,396 in reported general payments places this provider in the 65th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 260 | $275,032 |
| TrulicityDulaglutide | 184 | $187,404 |
| JardianceEmpagliflozin | 145 | $110,309 |
| MounjaroTirzepatide | 89 | $99,018 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 50 | $67,098 |
| FarxigaDapagliflozin Propanediol | 45 | $45,558 |
| TradjentaLinagliptin | 45 | $28,029 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 57 | $19,537 |
| RybelsusSemaglutide | 17 | $19,173 |
| Humulin R U-500Insulin Regular, Human | 11 | $15,461 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $15,275 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 135 | $14,707 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $12,533 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $11,024 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $9,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $214 | $307,269318 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $36 | $286,422273 claims |
| Boehringer IngelheimJardiance, Tradjenta | $296 | $138,338190 claims |
| AstraZenecaFarxiga | $230 | $45,55845 claims |
| AbbVieSynthroid | $29 | $1,21815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Hermiston
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
- Patricia HopsonCorvallis$166K
- Eric OrwollPortland$94K
- Paul DuellPortland$91K
- Sergio FazioPortland$88K
- Nancy CuroshPortland$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.